organization · Reporting owner
ALS Invest 1 B.V.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Amylyx Pharmaceuticals, Inc.
Report date July 06, 2022 · Filed July 08, 2022
Section 16 reporting ended · disclosed 2022-07-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,895,280 |
Last balance in matching sequence
After 2022-07-06 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2022-07-06 · Sale · Disposed 18,312 · Balance 5,937,577 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.975, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4) and (5) to this Form 4. F2: The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person. Row 2 · 2022-07-06 · Sale · Disposed 10,395 · Balance 5,927,182 F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.99, inclusive. F2: The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person. Row 3 · 2022-07-06 · Sale · Disposed 29,595 · Balance 5,897,587 F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.73, inclusive. F2: The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person. Row 4 · 2022-07-06 · Sale · Disposed 2,307 · Balance 5,895,280 F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.03 to $22.655, inclusive. F2: The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.975, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4) and (5) to this Form 4.
F2: The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.99, inclusive.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.73, inclusive.
F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.03 to $22.655, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2022 Filed Jul 8, 2022 18:44 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 2,307 | $22.42 | $51,722.94 |
DisclosureSEC source: 0000899243-22-025847 · doc4.xml · nonDerivative · entry 4 ALS Invest 1 B.V. · CIK 0001920501 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,895,280 F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.03 to $22.655, inclusive. F2 · ownership.direct: The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 18:44 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 29,595 | $21.32 | $630,965.40 |
DisclosureSEC source: 0000899243-22-025847 · doc4.xml · nonDerivative · entry 3 ALS Invest 1 B.V. · CIK 0001920501 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,897,587 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.73, inclusive. F2 · ownership.direct: The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 18:44 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 10,395 | $20.60 | $214,137.00 |
DisclosureSEC source: 0000899243-22-025847 · doc4.xml · nonDerivative · entry 2 ALS Invest 1 B.V. · CIK 0001920501 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,927,182 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.99, inclusive. F2 · ownership.direct: The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 18:44 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 18,312 | $19.54 | $357,816.48 |
DisclosureSEC source: 0000899243-22-025847 · doc4.xml · nonDerivative · entry 1 ALS Invest 1 B.V. · CIK 0001920501 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,937,577 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.975, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4) and (5) to this Form 4. F2 · ownership.direct: The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person. Read SEC document |
| January 11, 2022 Filed May 5, 2022 16:46 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries B Preferred Stock · Derivative | 4,826,503 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-016853 · doc4.xml · derivative · entry 4 ALS Invest 1 B.V. · CIK 0001920501 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,826,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F2 · ownership.direct: The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person. Read SEC document |
| January 11, 2022 Filed May 5, 2022 16:46 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries A Preferred Stock · Derivative | 1,129,386 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-016853 · doc4.xml · derivative · entry 3 ALS Invest 1 B.V. · CIK 0001920501 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,129,386 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F2 · ownership.direct: The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person. Read SEC document |
| January 11, 2022 Filed May 5, 2022 16:46 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionCommon Stock | 4,826,503 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-016853 · doc4.xml · nonDerivative · entry 2 ALS Invest 1 B.V. · CIK 0001920501 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,955,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F2 · ownership.direct: The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person. Read SEC document |
| January 11, 2022 Filed May 5, 2022 16:46 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionCommon Stock | 1,129,386 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-016853 · doc4.xml · nonDerivative · entry 1 ALS Invest 1 B.V. · CIK 0001920501 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,129,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F2 · ownership.direct: The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.